Treatment of Advanced Renal Cell Carcinoma: Immunotherapies Have Demonstrated Overall Survival Benefits While Targeted Therapies Have Not

CONTEXT: Current guidelines suggest several targeted therapies (TTs) and immunotherapies (ITs) in the treatment of advanced or metastatic renal cell carcinoma (mRCC). Ideal sequencing of these treatments is unclear. OBJECTIVE: The primary objective was to evaluate the overall survival (OS) data of t...

Descripción completa

Detalles Bibliográficos
Autores principales: Hemminki, Otto, Perlis, Nathan, Bjorklund, Johan, Finelli, Antonio, Zlotta, Alexandre R., Hemminki, Akseli
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Review – Kidney Cancer
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8317793/
https://www.ncbi.nlm.nih.gov/pubmed/34337479
http://dx.doi.org/10.1016/j.euros.2020.11.003

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8317793/
https://www.ncbi.nlm.nih.gov/pubmed/34337479
http://dx.doi.org/10.1016/j.euros.2020.11.003

Ejemplares similares